LXRX Overview

Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.

Wall Street analysts forecast LXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXRX is4.03 USD with a low forecast of 2.10 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lexicon Pharmaceuticals Inc revenue for the last quarter amounts to 21.10M USD, increased 1572.11

Lexicon Pharmaceuticals Inc. EPS for the last quarter amounts to -0.00 USD, decreased -100.00

Lexicon Pharmaceuticals Inc (LXRX) has 81 emplpoyees as of May 12 2026.

Today LXRX has the market capitalization of 1.03B USD.